Stocktoria
Vor Biopharma Inc. VOR
Nasdaq · XNAS · stock · Biological Products, (No Diagnostic Substances) · website · IPO 2021-02-05
Chart by TradingView
2/9
Piotroski F — financial health
-7.63
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Operating income | -$371.6M | -$121.2M | -$126.0M | -$93.4M | -$69.0M |
| Net income | -$696.0M | -$116.9M | -$117.9M | -$92.1M | -$68.9M |
| Operating cash flow | -$142.7M | -$99.7M | -$100.3M | -$85.1M | -$69.1M |
| Free cash flow | -$143.7M | -$99.9M | -$101.4M | -$93.6M | -$73.0M |
| Total assets | $464.1M | $142.9M | $198.1M | $299.4M | $242.6M |
| Total liabilities | $628.4M | $46.2M | $47.4M | $48.8M | $26.3M |
| Shareholders' equity | -$164.3M | -$96.7M | $150.7M | $250.6M | $216.3M |
| Ratios | |||||
| Return on assets | -150.0% | -81.8% | -59.5% | -30.8% | -28.4% |
| Return on equity | 423.6% | 120.9% | -78.2% | -36.7% | -31.9% |
| Current ratio | 18.20 | 5.19 | 9.04 | 18.06 | 21.12 |
Notable holders (13F)
| Investor | Shares | Value |
|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | 128,839 | $2.3M |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -7.63 (distress)
- Working capital / assets 0.933
- Retained earnings / assets -2.484
- EBIT / assets -0.801
- Equity / liabilities -0.261
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001817229 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.